- Fiscal year changed from December 31 to March 31
- Consolidated revenues of $55.3 million for the year ending March 31, 2014; Up $50.9 million
- Results include consolidation of one quarter’s results from Money-On-Mobile (India)
- Results include consolidation of four quarters of results from Calpian Commerce (domestic)
- Consolidated assets of $48.1 million for the year ending March 31, 2014
- Total equity of $15 million
Galmed Pharmaceuticals Ltd. (GLMD) (Galmed), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.
First Half 2014 Financial Summary:
- Reported cash and cash equivalents totaling $37.4 million on June 30, 2014, compared with $137,000 at December 31,
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2014.
Fourth Quarter and Recent Business Highlights:
-- Procured a quarterly record high of more than 100 implants -- Quarterly revenue increased 38% over the same prior year period result
NXT-ID, Inc., (NXTD:OTCQB) a biometric authentication company focused on the growing m-commerce market, updates participants on its current social media competition “Show us your Wallet”, for its next generation smart wallet, Wocket™.
The social media competition was created to show the evolution of the wallet from a bulky traditional wallet stuffed with credit cards and gift cards to a sleek, secure Wocket™ … Read more
SurePure, Inc. (OTC QB: SURP), a global leader in liquid photopurification, has today announced preliminary results for an additional commercial application of its patented photopurification technology in the South African dairy industry.
Driven primarily by a desire to save energy by using cold-processing rather than pasteurization in the manufacture of cheese, Oaksprings Dairy in Kwa-Zulu Natal, South Africa, has been utilizing SurePure’s technology. Oaksprings has … Read more
NXT-ID, Inc., (NXTD:OTCQB) a biometric authentication company focused on the growing m-commerce market, announces its next generation smart wallet, Wocket™, was recently the topic of an interview on Boomer Times. Host Anita Finley interviewed Gino Pereira, CEO of NXT-ID, on July 9th for over thirty minutes.
Mr. Gino Pereira explains how the Wocket will replace old bulky wallets full of credit cards and walks host … Read more
Galmed Pharmaceuticals Ltd. (GLMD) (“Galmed”), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that the U.S. Food and Drug Administration, or the FDA, cleared Galmed’s Investigational New Drug, or IND, application. Such clearance will permit Galmed to conduct clinical trials of its product candidate, aramchol, … Read more
Calpian Commerce, the U.S. payment processing division of Calpian Inc. (CLPI), has partnered with Yiftee to enable their merchant partners to opt in to an online and mobile gifting service for people who want to surprise and delight their employees, customers, friends and family. The eGift platform is provided to merchants at no cost and with no technology implementation requirement for those who … Read more
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment with VGX-3100, Inovio’s HPV16/18-specific immunotherapy, resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study’s primary endpoint. In addition, the trial demonstrated … Read more
Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™, has entered into a new collaboration agreement with the University College Cork (UCC) School of Pharmacy in Cork, Ireland, of the National University of Ireland (NUI), focusing on development of hemostasis and sealant products.
Arch is a medical device company developing a novel approach to stop bleeding (hemostasis) and … Read more